Welcome to our dedicated page for Tdk news (Ticker: TTDKF), a resource for investors and traders seeking the latest updates and insights on Tdk stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tdk's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tdk's position in the market.
TDK Corporation's subsidiary, TDK Ventures, has invested in green hydrogen company Verdagy to accelerate hydrogen electrolysis technology commercialization. This investment, part of TDK's commitment to clean technology, follows Verdagy's recent spin-off from Chemetry and aims to scale production of green hydrogen, crucial for decarbonizing industries. The $25M funding round, involving multiple investors, will support Verdagy in demonstrating its first commercial electrolyzer stack. Verdagy's innovative approach combines alkaline and proton-exchange electrolysis, promising low operational costs and compliance with U.S. Department of Energy targets.
TDK Corporation announced that its subsidiary, TDK Ventures, has invested in the biotech company Mekonos, which specializes in integrated molecular delivery chips for cell and gene therapies. This investment aligns with TDK's commitment to MEMS and BioMEMS innovations aimed at scaling healthcare solutions. The global market for cell and gene therapy is projected to reach $70.5 billion by 2026, growing at a CAGR of 52%. Mekonos has raised $25 million in a Series A round, with TDK joining other notable investors to advance novel therapies.
FAQ
What is the current stock price of Tdk (TTDKF)?
What is the market cap of Tdk (TTDKF)?
